To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Subcutaneous (SC) formulations of monoclonal antibodies (mAbs) allow faster and less invasive administration than intravenous (IV) routes, with comparable efficacy and safety. Beyond clinical equivalence, SC administration may reduce hospital resource use, improve patient experience, and increase treatment capacity, contributing to the sustainability of oncology care. This study aimed to develop and apply a hospital-based, multidisciplinary model to assess the economic and organizational impact of IV-to-SC transitions in oncology.
Methods
A scenario-based economic and organizational analysis was conducted using real-world institutional data from a high-volume oncology center, collected before price renegotiations, to estimate the budget impact and resource implications of transitioning from intravenous to subcutaneous mAbs. The analysis included drug acquisition, pharmacy preparation, nursing administration, chair occupancy, and staff time, with preparation costs estimated using Time-Driven Activity-Based Costing (TDABC). The model was applied to two mAbs (X and Y); eligible patients were identified through institutional registries, and scenario analyses simulated partial and complete IV-to-SC substitution across clinical settings.
Results
For antibody X, a full transition to SC administration increased annual treatment capacity by ~36 percent, with an additional drug expenditure of €123,354 and an overall budget impact of €66,778. For antibody Y, full SC adoption increased treatment capacity by ~19 percent, with an additional drug expenditure of €42,473 and a total budget impact of €6,671.
Conclusions
SC-related efficiency gains are highly context-dependent and are maximized in settings with latent capacity demand. The proposed hospital-based HTA framework supports evidence-based adoption strategies and informs sustainable pricing and organizational decision making in oncology.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.